Receptor for advanced glycation end product blockade enhances the chemotherapeutic effect of cisplatin in tongue squamous cell carcinoma by reducing autophagy and modulating the Wnt pathway.

Abstract

Tongue squamous cell carcinoma (TSCC) is one of the most severe types of cancer with poor outcomes. Cisplatin is used widely to treat cancer cells, but many patients develop acquired drug resistance. The receptor for advanced glycation end products (RAGE) is expressed widely in TSCC and associated with drug-induced chemotherapy resistance. However, the effect of RAGE and cisplatin on Tca-8113 cells remains unknown. We assayed the combined use of RAGE blockade and cisplatin effect on Tca-8113 cells' viability by MTT and apoptosis rate of Tca-8113 cells on RAGE blockade+cisplatin treatment; cisplatin alone; or RAGE blockade alone by flow cytometry. We observed the expressions of autophagy-related proteins beclin1, LC3II, p62; Wnt signaling-related proteins β-catenin, GSK3β, WNT5A, ROR-2; and apoptosis-related protein cleaved caspase-3, bcl-2-associated X proteins using western blot. We determined WNT5A and beclin1 expression on Tca-8113 cells by immunofluorescence. We further observed autophagy vacuoles by monodansylcadaverine staining. We found that RAGE blockade and cisplatin significantly decreased cell viability and increased the cell apoptosis rate compared with cisplatin alone. Furthermore, RAGE blockade suppressed the canonical Wnt pathway proteins β-catenin and GSK-3β, but upregulated noncanonical WNT5A and receptor ROR-2. We show that RAGE blockade suppressed the levels of autophagy-related protein LC3II/I, beclin1, accelerated degradation of autophagy for the increasing p62 expression, and increased cell apoptosis for the increasing expressions of cleaved caspase-3 and bcl-2-associated X proteins. We observed the location of WNT5A and beclin1 expressions on cells by immunofluorescence and their trends were consistent with western blotting. Taken together, our findings suggested that RAGE blockade+cisplatin improved chemotherapeutic effects by reducing autophagy and regulating Wnt/β-catenin to suppress the progression of TSCC.

• Authors: Ziming Zhao, Hongyu Wang, Liao Zhang, Xifan Mei, Jing Hu, Keqiang Huang
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 28 Issue 2 Pg. 187-196 (02 2017) ISSN: 1473-5741 [Electronic] England
• PMID: 27831944 (Publication Type: Journal Article)

Chemical References

• Antibodies
• Antigens, Neoplasm
• Antineoplastic Agents
• BECN1 protein, human
• Beclin-1
• CTNNB1 protein, human
• WNT5A protein, human
• Wnt-5a Protein
• beta Catenin
• ROR2 protein, human
• Receptor Tyrosine Kinase-like Orphan Receptors
• MOK protein, human
• Mitogen-Activated Protein Kinases
• Cisplatin

Topics

• Antibodies (immunology, pharmacology)
• Antigens, Neoplasm (biosynthesis, immunology)
• Antineoplastic Agents (pharmacology)
• Apoptosis (drug effects)
• Autophagy (drug effects)
• Beclin-1 (biosynthesis)
• Carcinoma, Squamous Cell (drug therapy, metabolism, pathology)
• Cell Line, Tumor
• Cisplatin (pharmacology)
• Drug Synergism
• Head and Neck Neoplasms (drug therapy, metabolism, pathology)
• Humans
• Mitogen-Activated Protein Kinases (antagonists & inhibitors, biosynthesis, immunology)
• Receptor Tyrosine Kinase-like Orphan Receptors (metabolism)
• Squamous Cell Carcinoma of Head and Neck
• Tongue Neoplasms (drug therapy, metabolism, pathology)
• Up-Regulation (drug effects)
• Wnt Signaling Pathway (drug effects)
• Wnt-5a Protein (biosynthesis)
• beta Catenin (metabolism)